Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Identification of genetic biomarkers for alloimmunization in sickle cell disease.

Meinderts SM, Gerritsma JJ, Sins JWR, de Boer M, van Leeuwen K, Biemond BJ, Rijneveld AW, Kerkhoffs JH, Habibi A, van Bruggen R, Kuijpers TW, van der Schoot E, Pirenne F, Fijnvandraat K, Tanck MW, van den Berg TK.

Br J Haematol. 2019 Jun 5. doi: 10.1111/bjh.15998. [Epub ahead of print]

PMID:
31168801
2.

BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease.

Atiq F, Fijnvandraat K, van Galen KPM, Laros-Van Gorkom BAP, Meijer K, de Meris J, Coppens M, Mauser-Bunschoten EP, Cnossen MH, van der Bom JG, Eikenboom J, Leebeek FWG; WiN study group.

Am J Hematol. 2019 Aug;94(8):E201-E205. doi: 10.1002/ajh.25499. Epub 2019 May 13. No abstract available.

PMID:
31037771
3.

Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study.

Schütte LM, Cnossen MH, van Hest RM, Driessens MHE, Fijnvandraat K, Polinder S, Beckers EAM, Coppens M, Eikenboom J, Laros-van Gorkom BAP, Meijer K, Nieuwenhuizen L, Mauser-Bunschoten EP, Leebeek FWG, Mathôt RAA, Kruip MJHA.

BMJ Open. 2019 Apr 23;9(4):e022719. doi: 10.1136/bmjopen-2018-022719.

4.

Extensive Ethnic Variation and Linkage Disequilibrium at the FCGR2/3 Locus: Different Genetic Associations Revealed in Kawasaki Disease.

Nagelkerke SQ, Tacke CE, Breunis WB, Tanck MWT, Geissler J, Png E, Hoang LT, van der Heijden J, Naim ANM, Yeung RSM, Levin ML, Wright VJ, Burgner DP, Ponsonby AL, Ellis JA, Cimaz R, Shimizu C, Burns JC, Fijnvandraat K, van der Schoot CE, van den Berg TK, de Boer M, Davila S, Hibberd ML, Kuijpers TW; International Kawasaki Disease Genetics Consortium.

Front Immunol. 2019 Mar 21;10:185. doi: 10.3389/fimmu.2019.00185. eCollection 2019.

5.

Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner.

Loomans JI, Stokhuijzen E, Peters M, Fijnvandraat K.

J Clin Transl Res. 2018 Feb 21;3(Suppl 2):351-357. eCollection 2018 Jul 30.

6.

Dynamic prediction of bleeding risk in thrombocytopenic preterm neonates.

Fustolo-Gunnink SF, Fijnvandraat K, Putter H, Ree IM, Caram-Deelder C, Andriessen P, d'Haens EJ, Hulzebos CV, Onland W, Kroon AA, Vijlbrief DC, Lopriore E, van der Bom JG.

Haematologica. 2019 Feb 28. pii: haematol.2018.208595. doi: 10.3324/haematol.2018.208595. [Epub ahead of print]

7.

The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH.

Makris M, Oldenburg J, Mauser-Bunschoten EP, Peerlinck K, Castaman G, Fijnvandraat K; subcommittee on Factor VIII, Factor IX and Rare Bleeding Disorders.

J Thromb Haemost. 2018 Dec;16(12):2530-2533. doi: 10.1111/jth.14315. Epub 2018 Nov 15. No abstract available.

PMID:
30430726
8.

Sports participation and physical activity in patients with von Willebrand disease.

Atiq F, Mauser-Bunschoten EP, Eikenboom J, van Galen KPM, Meijer K, de Meris J, Cnossen MH, Beckers EAM, Laros-van Gorkom BAP, Nieuwenhuizen L, van der Bom JG, Fijnvandraat K, Leebeek FWG; WiN study group.

Haemophilia. 2019 Jan;25(1):101-108. doi: 10.1111/hae.13629. Epub 2018 Nov 14.

PMID:
30427095
9.

The prevalence and burden of hand and wrist bleeds in von Willebrand disease.

van Deukeren D, Mauser-Bunschoten EP, Schutgens REG, Eikenboom J, Meijer K, Fijnvandraat K, Laros-van Gorkom BAP, Cnossen M, de Meris J, van der Bom JG, Leebeek FWG, van Galen KPM.

Haemophilia. 2019 Jan;25(1):e35-e38. doi: 10.1111/hae.13632. Epub 2018 Nov 5. No abstract available.

PMID:
30394622
10.

Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.

Preijers T, Hazendonk HCAM, Liesner R, Chowdary P, Driessens MHE, Hart D, Keeling D, Laros-van Gorkom BAP, van der Meer FJM, Meijer K, Fijnvandraat K, Leebeek FWG, Collins PW, Cnossen MH, Mathôt RAA; OPTI‐CLOT study group.

J Thromb Haemost. 2018 Nov;16(11):2196-2207. doi: 10.1111/jth.14292. Epub 2018 Oct 28.

PMID:
30394056
11.

Randomized Trial of Platelet-Transfusion Thresholds in Neonates.

Curley A, Stanworth SJ, Willoughby K, Fustolo-Gunnink SF, Venkatesh V, Hudson C, Deary A, Hodge R, Hopkins V, Lopez Santamaria B, Mora A, Llewelyn C, D'Amore A, Khan R, Onland W, Lopriore E, Fijnvandraat K, New H, Clarke P, Watts T; PlaNeT2 MATISSE Collaborators.

N Engl J Med. 2019 Jan 17;380(3):242-251. doi: 10.1056/NEJMoa1807320. Epub 2018 Nov 2.

PMID:
30387697
12.

Clinically relevant differences between assays for von Willebrand factor activity.

Boender J, Eikenboom J, van der Bom JG, Meijer K, de Meris J, Fijnvandraat K, Cnossen MH, Laros-van Gorkom BAP, van Heerde WL, Mauser-Bunschoten EP, de Maat MPM, Leebeek FWG; WiN Study Group.

J Thromb Haemost. 2018 Dec;16(12):2413-2424. doi: 10.1111/jth.14319. Epub 2018 Nov 20.

PMID:
30358069
13.

Are thrombocytopenia and platelet transfusions associated with major bleeding in preterm neonates? A systematic review.

Fustolo-Gunnink SF, Huisman EJ, van der Bom JG, van Hout FMA, Makineli S, Lopriore E, Fijnvandraat K.

Blood Rev. 2019 Jul;36:1-9. doi: 10.1016/j.blre.2018.10.001. Epub 2018 Oct 9. Review.

PMID:
30318111
14.

Long-Term Outcome after Joint Bleeds in Von Willebrand Disease Compared to Haemophilia A: A Post Hoc Analysis.

van Galen KPM, Timmer M, de Kleijn P, Leebeek FWG, Foppen W, Schutgens REG, Eikenboom J, Meijer K, Fijnvandraat K, Laros-van Gorkom BAP, Twisk JW, Mauser-Bunschoten EP, Fischer K; WiN Studygroup.

Thromb Haemost. 2018 Oct;118(10):1690-1700. doi: 10.1055/s-0038-1670704. Epub 2018 Oct 1.

PMID:
30273954
15.

Positioning extended half-life concentrates for future use: a practical proposal.

Nederlof A, Mathôt RAA, Leebeek FWG, Fijnvandraat K, Fischer K, Cnossen MH; “OPTI-CLOT” study group.

Haemophilia. 2018 Sep;24(5):e369-e372. doi: 10.1111/hae.13588. Epub 2018 Aug 24. No abstract available.

PMID:
30144218
16.

Preventing or Eradicating Factor VIII Antibody Formation in Patients with Hemophilia A: What Can We Learn from Other Disorders?

Hassan S, Fijnvandraat K, van der Bom JG, Gouw SC.

Semin Thromb Hemost. 2018 Sep;44(6):531-543. doi: 10.1055/s-0038-1666823. Epub 2018 Jul 25. Review.

PMID:
30045390
17.

Are low-molecular-weight heparins safe and effective in children? A systematic review.

Klaassen ILM, Sol JJ, Suijker MH, Fijnvandraat K, van de Wetering MD, Heleen van Ommen C.

Blood Rev. 2019 Jan;33:33-42. doi: 10.1016/j.blre.2018.06.003. Epub 2018 Jun 28.

PMID:
30041977
18.

Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease.

Atiq F, Meijer K, Eikenboom J, Fijnvandraat K, Mauser-Bunschoten EP, van Galen KPM, Nijziel MR, Ypma PF, de Meris J, Laros-van Gorkom BAP, van der Bom JG, de Maat MP, Cnossen MH, Leebeek FWG; WiN study group.

Br J Haematol. 2018 Jul;182(1):93-105. doi: 10.1111/bjh.15277. Epub 2018 May 16.

19.

Identifying Children with HEreditary Coagulation disorders (iCHEC): a protocol for a prospective cohort study.

Stokhuijzen E, Rand ML, Cnossen MH, Biss TT, James PD, Suijker MH, Peters M, van der Lee JH, Peters B, Meijer AB, Blanchette VS, Fijnvandraat K.

BMJ Open. 2018 May 3;8(5):e020686. doi: 10.1136/bmjopen-2017-020686.

20.

Perioperative replacement therapy in haemophilia B: An appeal to "B" more precise.

Hazendonk HCAM, Preijers T, Liesner R, Chowdary P, Hart D, Keeling D, Driessens MHE, Laros-van Gorkom BAP, van der Meer FJM, Meijer K, Fijnvandraat K, Leebeek FWG, Mathôt RAA, Collins PW, Cnossen MH.

Haemophilia. 2018 Jul;24(4):611-618. doi: 10.1111/hae.13469. Epub 2018 Apr 29.

PMID:
29707861
21.

Analysis of current perioperative management with Haemate® P/Humate P® in von Willebrand disease: Identifying the need for personalized treatment.

Hazendonk HCAM, Heijdra JM, de Jager NCB, Veerman HC, Boender J, van Moort I, Mathôt RAA, Meijer K, Laros-van Gorkom BAP, Eikenboom J, Fijnvandraat K, Leebeek FWG, Cnossen MH; “OPTI-CLOT” and “WIN” study group.

Haemophilia. 2018 May;24(3):460-470. doi: 10.1111/hae.13451. Epub 2018 Mar 24.

PMID:
29573506
22.

Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII.

Preijers T, van Moort I, Fijnvandraat K, Leebeek FWG, Cnossen MH, Mathôt RAA; ‘OPTI-CLOT’ Study Group.

Thromb Haemost. 2018 Mar;118(3):514-525. doi: 10.1055/s-0038-1623531. Epub 2018 Mar 13.

PMID:
29534249
23.

Inhibitors in Nonsevere Hemophilia A: What Is Known and Searching for the Unknown.

Abdi A, Linari S, Pieri L, Voorberg J, Fijnvandraat K, Castaman G.

Semin Thromb Hemost. 2018 Sep;44(6):568-577. doi: 10.1055/s-0037-1621717. Epub 2018 Feb 13. Review.

PMID:
29439277
24.

Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?

Hazendonk HCAM, van Moort I, Mathôt RAA, Fijnvandraat K, Leebeek FWG, Collins PW, Cnossen MH; OPTI-CLOT study group.

Blood Rev. 2018 Jul;32(4):265-271. doi: 10.1016/j.blre.2018.01.001. Epub 2018 Jan 31. Review.

25.

Male gender, school attendance and sports participation are positively associated with health-related quality of life in children and adolescents with congenital bleeding disorders.

Limperg PF, Joosten MMH, Fijnvandraat K, Peters M, Grootenhuis MA, Haverman L.

Haemophilia. 2018 May;24(3):395-404. doi: 10.1111/hae.13420. Epub 2018 Feb 8.

PMID:
29418040
26.

Desmopressin in moderate hemophilia A patients: a treatment worth considering.

Loomans JI, Kruip MJHA, Carcao M, Jackson S, van Velzen AS, Peters M, Santagostino E, Platokouki H, Beckers E, Voorberg J, van der Bom JG, Fijnvandraat K; RISE consortium.

Haematologica. 2018 Mar;103(3):550-557. doi: 10.3324/haematol.2017.180059. Epub 2018 Jan 5.

27.

Circulating Angiogenic Mediators in Patients with Moderate and Severe von Willebrand Disease: A Multicentre Cross-Sectional Study.

Groeneveld DJ, Sanders YV, Adelmeijer J, Mauser-Bunschoten EP, van der Bom JG, Cnossen MH, Fijnvandraat K, Laros-van Gorkom BAP, Meijer K, Lisman T, Eikenboom J, Leebeek FWG.

Thromb Haemost. 2018 Jan;118(1):152-160. doi: 10.1160/TH17-06-0397. Epub 2018 Jan 5.

PMID:
29304535
28.

Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review.

Sins JWR, Mager DJ, Davis SCAT, Biemond BJ, Fijnvandraat K.

Blood Adv. 2017 Aug 22;1(19):1598-1616. doi: 10.1182/bloodadvances.2017007211. eCollection 2017 Aug 22. Review.

29.

Intracranial 4D flow magnetic resonance imaging reveals altered haemodynamics in sickle cell disease.

Václavů L, Baldew ZAV, Gevers S, Mutsaerts HJMM, Fijnvandraat K, Cnossen MH, Majoie CB, Wood JC, VanBavel E, Biemond BJ, van Ooij P, Nederveen AJ.

Br J Haematol. 2018 Feb;180(3):432-442. doi: 10.1111/bjh.15043. Epub 2017 Dec 21.

PMID:
29270975
30.

Thrombocytopenia in neonatal sepsis: Incidence, severity and risk factors.

Ree IMC, Fustolo-Gunnink SF, Bekker V, Fijnvandraat KJ, Steggerda SJ, Lopriore E.

PLoS One. 2017 Oct 4;12(10):e0185581. doi: 10.1371/journal.pone.0185581. eCollection 2017.

31.

Nonclassical FCGR2C haplotype is associated with protection from red blood cell alloimmunization in sickle cell disease.

Meinderts SM, Sins JWR, Fijnvandraat K, Nagelkerke SQ, Geissler J, Tanck MW, Bruggeman C, Biemond BJ, Rijneveld AW, Kerkhoffs JH, Pakdaman S, Habibi A, van Bruggen R, Kuijpers TW, Pirenne F, van den Berg TK.

Blood. 2017 Nov 9;130(19):2121-2130. doi: 10.1182/blood-2017-05-784876. Epub 2017 Sep 12.

32.

Differences between Platelets Derived from Neonatal Cord Blood and Adult Peripheral Blood Assessed by Mass Spectrometry.

Stokhuijzen E, Koornneef JM, Nota B, van den Eshof BL, van Alphen FPJ, van den Biggelaar M, van der Zwaan C, Kuijk C, Mertens K, Fijnvandraat K, Meijer AB.

J Proteome Res. 2017 Oct 6;16(10):3567-3575. doi: 10.1021/acs.jproteome.7b00298. Epub 2017 Aug 30.

PMID:
28823163
33.

To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.

Hartholt RB, van Velzen AS, Peyron I, Ten Brinke A, Fijnvandraat K, Voorberg J.

Blood Rev. 2017 Sep;31(5):339-347. doi: 10.1016/j.blre.2017.07.001. Epub 2017 Jul 4. Review.

PMID:
28716211
34.

Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment.

Andersson NG, Auerswald G, Barnes C, Carcao M, Dunn AL, Fijnvandraat K, Hoffmann M, Kavakli K, Kenet G, Kobelt R, Kurnik K, Liesner R, Mäkipernaa A, Manco-Johnson MJ, Mancuso ME, Molinari AC, Nolan B, Perez Garrido R, Petrini P, Platokouki HE, Shapiro AD, Wu R, Ljung R.

Br J Haematol. 2017 Oct;179(2):298-307. doi: 10.1111/bjh.14844. Epub 2017 Jul 12.

PMID:
28699675
35.

In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.

Preijers T, Hazendonk HCAM, Fijnvandraat K, Leebeek FWG, Cnossen MH, Mathôt RAA.

J Thromb Haemost. 2017 Sep;15(9):1737-1746. doi: 10.1111/jth.13771. Epub 2017 Aug 9.

PMID:
28688133
36.

Effect of N-acetylcysteine on pain in daily life in patients with sickle cell disease: a randomised clinical trial.

Sins JWR, Fijnvandraat K, Rijneveld AW, Boom MB, Kerkhoffs JH, van Meurs AH, de Groot MR, Heijboer H, Dresse MF, Lê PQ, Hermans P, Vanderfaeillie A, Van Den Neste EW, Benghiat FS, Kesse-Adu R, Delannoy A, Efira A, Azerad MA, de Borgie CA, Biemond BJ.

Br J Haematol. 2018 Aug;182(3):444-448. doi: 10.1111/bjh.14809. Epub 2017 Jun 23. No abstract available.

37.

Mortality caused by intracranial bleeding in non-severe hemophilia A patients: reply.

Loomans JI, Fijnvandraat K.

J Thromb Haemost. 2017 Aug;15(8):1710-1711. doi: 10.1111/jth.13756. Epub 2017 Jul 5. No abstract available.

38.

Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study.

van Galen KPM, de Kleijn P, Foppen W, Eikenboom J, Meijer K, Schutgens REG, Fischer K, Cnossen MH, de Meris J, Fijnvandraat K, van der Bom JG, Laros-van Gorkom BAP, Leebeek FWG, Mauser-Bunschoten EP; Win study group.

Haematologica. 2017 Sep;102(9):1486-1493. doi: 10.3324/haematol.2017.168617. Epub 2017 Jun 1.

39.

Joint assessment in von Willebrand disease. Validation of the Haemophilia Joint Health score and Haemophilia Activities List.

van Galen KPM, Timmer MA, de Kleijn P, Fischer K, Foppen W, Schutgens REG, Eikenboom J, Meijer K, Cnossen MH, Fijnvandraat K, van der Bom JG, Laros-van Gorkom BAP, Leebeek FWG, Mauser-Bunschoten EP, Win Study Group OBOT.

Thromb Haemost. 2017 Aug 1;117(8):1465-1470. doi: 10.1160/TH16-12-0967. Epub 2017 May 11.

PMID:
28492695
40.

Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state.

Sins JWR, Schimmel M, Luken BM, Nur E, Zeerleder SS, van Tuijn CFJ, Brandjes DPM, Kopatz WF, Urbanus RT, Meijers JCM, Biemond BJ, Fijnvandraat K.

J Thromb Haemost. 2017 Jul;15(7):1392-1402. doi: 10.1111/jth.13728. Epub 2017 Jun 5.

41.

Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study.

van Velzen AS, Eckhardt CL, Peters M, Leebeek FWG, Escuriola-Ettingshausen C, Hermans C, Keenan R, Astermark J, Male C, Peerlinck K, le Cessie S, van der Bom JG, Fijnvandraat K.

J Thromb Haemost. 2017 Jul;15(7):1422-1429. doi: 10.1111/jth.13711. Epub 2017 Jun 2.

42.

Mortality caused by intracranial bleeding in non-severe hemophilia A patients.

Loomans JI, Eckhardt CL, Reitter-Pfoertner SE, Holmström M, van Gorkom BL, Leebeek FWG, Santoro C, Haya S, Meijer K, Nijziel MR, van der Bom JG, Fijnvandraat K.

J Thromb Haemost. 2017 Jun;15(6):1115-1122. doi: 10.1111/jth.13693. Epub 2017 May 4.

43.

Psychosocial care for children with haemophilia and their parents in the Netherlands.

Limperg PF, Haverman L, Beijlevelt M, van der Pot M, Zaal G, de Boer WA, Fijnvandraat K, Peters M, Grootenhuis MA.

Haemophilia. 2017 May;23(3):362-369. doi: 10.1111/hae.13186. Epub 2017 Mar 21. Review.

PMID:
28321962
44.

Variation in baseline factor VIII concentration in a retrospective cohort of mild/moderate hemophilia A patients carrying identical F8 mutations.

Loomans JI, van Velzen AS, Eckhardt CL, Peters M, Mäkipernaa A, Holmstrom M, Brons PP, Dors N, Haya S, Voorberg J, van der Bom JG, Fijnvandraat K.

J Thromb Haemost. 2017 Feb;15(2):246-254. doi: 10.1111/jth.13581. Epub 2017 Feb 3.

45.

Daily pain in adults with sickle cell disease-a different perspective.

van Tuijn CF, Sins JW, Fijnvandraat K, Biemond BJ.

Am J Hematol. 2017 Feb;92(2):179-186. doi: 10.1002/ajh.24612.

46.

Current view and outcome of ITI therapy - A change over time?

Holstein K, Batorova A, Carvalho M, Fijnvandraat K, Holme P, Kavakli K, Lambert T, Rocino A, Jiménez-Yuste V, Astermark J; European Haemophilia Therapy Strategy Board (EHTSB).

Thromb Res. 2016 Dec;148:38-44. doi: 10.1016/j.thromres.2016.10.015. Epub 2016 Oct 15.

PMID:
27770665
47.

A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients.

Hazendonk H, Fijnvandraat K, Lock J, Driessens M, van der Meer F, Meijer K, Kruip M, Gorkom BL, Peters M, de Wildt S, Leebeek F, Cnossen M, Mathôt R; “OPTI-CLOT” study group.

Haematologica. 2016 Oct;101(10):1159-1169. Epub 2016 Jul 6.

48.

In Vivo T1 of Blood Measurements in Children with Sickle Cell Disease Improve Cerebral Blood Flow Quantification from Arterial Spin-Labeling MRI.

Václavů L, van der Land V, Heijtel DF, van Osch MJ, Cnossen MH, Majoie CB, Bush A, Wood JC, Fijnvandraat KJ, Mutsaerts HJ, Nederveen AJ.

AJNR Am J Neuroradiol. 2016 Sep;37(9):1727-32. doi: 10.3174/ajnr.A4793. Epub 2016 May 26.

49.

Early-Onset Thrombocytopenia in Small-For-Gestational-Age Neonates: A Retrospective Cohort Study.

Fustolo-Gunnink SF, Vlug RD, Smits-Wintjens VE, Heckman EJ, Te Pas AB, Fijnvandraat K, Lopriore E.

PLoS One. 2016 May 13;11(5):e0154853. doi: 10.1371/journal.pone.0154853. eCollection 2016.

50.

Emerging Issues in Diagnosis, Biology, and Inhibitor Risk in Mild Hemophilia A.

Castaman G, Eckhardt C, van Velzen A, Linari S, Fijnvandraat K.

Semin Thromb Hemost. 2016 Jul;42(5):507-12. doi: 10.1055/s-0036-1571309. Epub 2016 May 5. Review.

PMID:
27148839

Supplemental Content

Loading ...
Support Center